|
||
J. Cell Biol.,
Volume 141, Number 4, May 18, 1998 1053-1059
Receptor CCR7






* Laboratory of Immunology and Vascular Biology, Department of Pathology; and The Digestive Disease Center, Department of
Medicine, Stanford University Medical School, Stanford, California 94305; The
The Center for Molecular Biology and Medicine,
Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304; § LeukoSite, Inc., Cambridge, Massachusetts 02142;
Gryphon Sciences, South San Francisco, California 94080; and ¶ Department of Immunology, DNAX Research Institute of
Molecular and Cellular Biology, Palo Alto, California 94304
chemokine known as 6-C-kine, secondary lymphoid-tissue chemokine (SLC), TCA4, or
Exodus-2 (herein referred to as 6CK/SLC) can trigger
rapid integrin-dependent arrest of lymphocytes rolling under physiological shear and is highly expressed by
high endothelial venules, specialized vessels involved in
lymphocyte homing from the blood into lymph nodes
and Peyer's patches. We show that 6CK/SLC is an agonist for the lymphocyte chemoattractant receptor,
CCR7 (EBI-1, BLR-2), previously described as a receptor for the related
chemokine MIP-3
(ELC or
Exodus-3). Moreover, 6CK/SLC and MIP-3
attract
the same major populations of circulating lymphocytes, including naive and memory T cells > B cells (but not
natural killer cells); desensitization to MIP-3
inhibits
lymphocyte chemotaxis to 6CK/SLC but not to the
chemokine SDF-1 (stromal cell-derived factor); and
6CK/SLC competes for MIP-3
binding to resting
mouse lymphocytes. The findings suggest that the
majority of circulating lymphocytes respond to 6CK/SLC
and MIP-3
in large part through their common receptor CCR7 and that these molecules may be important mediators of physiological lymphocyte recirculation in vivo.
This article has been cited by other articles:
|
|